MAYINGLONG PHARMACEUTICAL GROUP CO., LTD.

Mayinglong Pharmaceutical Group Co., LTD.

600993

CNE000001HN2

Pharmaceuticals

End-of-day quote Shanghai S.E. Other stock markets 06:00:00 2024-05-12 pm EDT			5-day change	1st Jan Change
29.05 ^CNY	+0.21%		+1.57%	+20.14%

Apr. 19	Mayinglong Pharmaceutical Group Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI
Apr. 17	Mayinglong Pharmaceutical Receives Registration Approval for New Colorectal Treatment	MT

Mayinglong Pharmaceutical Group Co., Ltd. Announces Earnings Results for the Year 2018

April 25, 2019

Mayinglong Pharmaceutical Group Co., LTD. announced earnings results for the year 2018. For the year, the company reported basic earnings per share of CNY 0.41.

Latest news about Mayinglong Pharmaceutical Group Co., LTD.

Mayinglong Pharmaceutical Group Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024	Apr. 19	CI
Mayinglong Pharmaceutical Receives Registration Approval for New Colorectal Treatment	Apr. 17	MT
Mayinglong Pharmaceutical Group Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023	Apr. 12	CI
Mayinglong Pharmaceutical Group Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2023	23-10-27	CI
Mayinglong Pharmaceutical Group Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2023	23-08-25	CI
Mayinglong Pharmaceutical Group Co., LTD. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-04-28	CI
Mayinglong Pharmaceutical Group Co., LTD. Reports Earnings Results for the Full Year Ended December 31, 2022	23-04-07	CI
Hangzhou Yunbai Pharmaceutical Technology Co., Ltd. agreed to acquire 86.816% of stake in Shenzhen Daphne Pharmaceautical Co.,Ltd from from Mayinglong Pharmaceutical Group Co., LTD., Huayi Development Co., Ltd., China Bao An Co., Ltd and Guofa Jianfu Industrial Co., Ltd. for approximately CNY 260 million.	22-12-13	CI
Mayinglong Pharmaceutical Group Co., LTD. Reports Earnings Results for the Nine Months Ended September 30, 2022	22-10-25	CI
Mayinglong Pharmaceutical Group Co., LTD. Reports Earnings Results for the Half Year Ended June 30, 2022	22-08-19	CI
Mayinglong Pharmaceutical Group Co., LTD. Reports Earnings Results for the First Quarter Ended March 31, 2022	22-04-26	CI
Mayinglong Pharmaceutical Group Co., LTD. Reports Earnings Results for the Full Year Ended December 31, 2021	22-03-22	CI
Mayinglong Pharmaceutical Group Co., LTD. Reports Earnings Results for the Nine Months Ended September 30, 2021	21-10-22	CI
Mayinglong Pharmaceutical Group Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2021	21-08-20	CI
Mayinglong Pharmaceutical Group Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2021	21-04-23	CI
Mayinglong Pharmaceutical Group Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2020	21-03-25	CI
Mayinglong Pharmaceutical Group Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2020	20-10-23	CI
Mayinglong Pharmaceutical Group Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2020	20-08-21	CI
Mayinglong Pharmaceutical Group Co., Ltd. Announces Cash Dividend for the Year 2019, Payable on July 30, 2020	20-07-21	CI
Mayinglong Pharmaceutical Group Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2019	20-04-24	CI
Mayinglong Pharmaceutical Group Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2020	20-04-24	CI
Mayinglong Pharmaceutical Group Co., Ltd. Provides Earnings Guidance for the Year 2019	20-01-20	CI
Mayinglong Pharmaceutical Group Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2019	19-10-23	CI
Mayinglong Pharmaceutical Group Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2019	19-08-23	CI
Mayinglong Pharmaceutical Group Co., Ltd Announces the Cash Dividend for 2018, Payable on July 26, 2019	19-07-17	CI

Chart Mayinglong Pharmaceutical Group Co., LTD.

Duration

Period

Chart Mayinglong Pharmaceutical Group Co., LTD.

More charts

Mayinglong Pharmaceutical Group Co., Ltd. is a China-based company, principally engaged in pharmaceutical production, retailing and wholesaling businesses. The Company's pharmaceutical products are classified as drugs for hemorrhoid, including diosmin tablets, suppositories, pastes and granules, among others; drugs for cough, including levodropropizine oral solution and compound glycyrrhiza oral solution, as well as drugs for skin injuries, including products such as erythromycin ointment. The Company also provides specialty drugs. The Company is also engaged in the production and distribution of eye cream products with the brand named Mayinglong BaBao, as well as the provision of hospital clinical service. The Company distributes its products mainly in domestic markets.

Sector

Pharmaceuticals

Calendar

2024-08-25 - Q2 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Sector Generic Pharmaceuticals

	1st Jan change	Capi.
MAYINGLONG PHARMACEUTICAL GROUP CO., LTD.	+20.14%	1.73B
SUN PHARMACEUTICAL INDUSTRIES LTD.	+21.09%	43.27B
OTSUKA HOLDINGS CO., LTD.	+25.39%	22.92B
SANDOZ GROUP AG	+19.22%	15.43B
CIPLA LIMITED	+13.51%	12.95B
ZYDUS LIFESCIENCES LIMITED	+44.01%	11.83B
ONO PHARMACEUTICAL CO., LTD.	-6.70%	6.91B
THE MEDICINES COMPANY	-0.05%	6.79B
STADA ARZNEIMITTEL	-8.87%	5.73B
ASPEN PHARMACARE HOLDINGS LIMITED	+13.26%	5.55B

Generic Pharmaceuticals